SteadyMed Therapeutics (NSDQ:STDY) today detailed the development of its lead drug product candidate, Trevyent (treprostinil sodium), for the treatment of pulmonary arterial hypertension using its PatchPump tech at the Parenteral Drug Assn. Conference in Huntington Beach, Calif.
PatchPump is the 1st single-use, wearable, pre-filled pump and treprostinil will be the 1st drug integrated with the delivery system, according to the San Ramon, Calif.-based company.
The pump uses a self-powered expanding battery actuator, a semi-flexible container, a printer circuit board assembly for controlling the delivery rate, a proprietary infusion set, and an adhesive patch.
Get the full story at our sister site, Drug Delivery Business News.
The post SteadyMed details commercialization plans for Trevyent appeared first on MassDevice.
from MassDevice http://ift.tt/2ej9h70
Cap comentari:
Publica un comentari a l'entrada